PDRI Rates Among CAPD Patients at a Tertiary University Hospital: A 5-Year Retrospective Study

July 6, 2021 updated by: Phramongkutklao College of Medicine and Hospital

Peritoneal Dialysis-Related Infection Rates and Outcomes of Antibiotic Treatments Among Continuous Ambulatory Peritoneal Dialysis Patients at a Tertiary University Hospital: A 5-Year Retrospective Study

Peritoneal dialysis-related infection is a complication that leads to peritoneal dialysis catheter removal or patient death. The present study aimed to investigate peritoneal dialysis-related infection rates, causative pathogens, appropriation of antibiotic use, treatment outcomes and trend in antimicrobial resistance of causative pathogens.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

135

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Thailand
    • Bangkok
      • Ratchathewi, Bangkok, Thailand, 10400
        • Phramongkutklao Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients who were undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD) at CAPD clinic, Phramongkutklao Hospital.

Description

Inclusion Criteria:

  1. Patients who were at least 18 years old.
  2. Patients who were diagnosed with stage 5 chronic kidney disease (eGFR < 15 ml/min/1.73m^2).
  3. Patients who were undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD) at CAPD clinic, Phramongkutklao Hospital during January 1, 2016 to December 31, 2020.

Exclusion Criteria:

  1. Patients with incomplete data records that invalid to include in the process of data analysis
  2. Patients who were not treated and started their first CAPD at CAPD clinic, Phramongkutklao Hospital.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of peritoneal dialysis-related infection
Time Frame: January 1, 2016 to December 31, 2020
Retrospective data collection from patients' medical records
January 1, 2016 to December 31, 2020
Treatment outcomes of peritoneal dialysis-related infection
Time Frame: January 1, 2016 to December 31, 2020
Retrospective data collection from patients' medical records
January 1, 2016 to December 31, 2020

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Causative pathogens of peritoneal dialysis-related infection
Time Frame: January 1, 2016 to December 31, 2020
Retrospective data collection from patients' medical records
January 1, 2016 to December 31, 2020
Appropriation of antibiotic use in the treatments of peritoneal dialysis-related infection
Time Frame: January 1, 2016 to December 31, 2020
Retrospective data collection from patients' medical records
January 1, 2016 to December 31, 2020

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Phramongkutklao College of Medicine and Hospital

Collaborators

Silpakorn University Faculty of Pharmacy

Investigators

  • Study Chair: Pamila Tasanavipas, MD, Phramongkutklao hospital and College of Medicine
  • Study Director: Daraporn Rungprai, BCP, Faculty of Pharmacy, Silpakorn University
  • Principal Investigator: Vorada Pengsong, Faculty of Pharmacy, Silpakorn University
  • Principal Investigator: Vattanai Dhamnimitchok, Faculty of Pharmacy, Silpakorn University
  • Principal Investigator: Vilai Wisuthip, Faculty of Pharmacy, Silpakorn University
  • Principal Investigator: Supichaya Hluangbumroong, Faculty of Pharmacy, Silpakorn University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 24, 2021

Primary Completion (Actual)

March 11, 2021

Study Completion (Actual)

April 14, 2021

Study Registration Dates

First Submitted

June 25, 2021

First Submitted That Met QC Criteria

June 25, 2021

First Posted (Actual)

July 6, 2021

Study Record Updates

Last Update Posted (Actual)

July 12, 2021

Last Update Submitted That Met QC Criteria

July 6, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PDRI-2020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peritoneal Dialysis-related Infection

Clinical Trials on PDRI patients

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe